Understanding CTD Modules for Regulatory Submissions in Pharma

Published on 21/12/2025

A Practical Overview of CTD Modules for Regulatory Submissions

The Common Technical Document (CTD) format has become the standard structure for regulatory submissions in the pharmaceutical industry across major markets. Designed by the International Council for Harmonisation (ICH), the CTD streamlines submissions for new drug applications, allowing for harmonization across regions like the US, EU, and Japan.

This tutorial will guide pharma professionals and clinical trial documentation experts through the structure and purpose of each CTD module. You’ll learn best practices for compiling Modules 1 through 5, along with formatting, compliance, and submission considerations to ensure your dossiers are regulator-ready.

Table of Contents

What is the CTD Format?

The CTD is a standardized format for drug registration applications and comprises five major modules. It was created to simplify and unify the regulatory review process across agencies such as USFDA, EMA, Health Canada, and others.

The CTD can be submitted either in paper or electronic format (eCTD), with the latter being the preferred method by most agencies. It plays a crucial role in the acceptance of NDAs, ANDAs, and marketing authorizations.

Each module contains different types of data — administrative, quality, nonclinical, and clinical — all of which

support the safety, efficacy, and quality of the product being registered.

Module 1: Regional Administrative Information

Module 1 is specific to the region where the application is being submitted. It contains:

Application forms
Cover letters
Product labeling and package inserts
Prescribing information
Certificates of Suitability (CEP), if applicable
Information on patent status and environmental assessments

This module is not harmonized across countries, and applicants must follow each region’s specific requirements. Refer to agency websites for templates and checklists. For example, the EMA and pharma regulatory compliance bodies provide country-specific instructions.

Module 2: Common Technical Document Summaries

Module 2 provides high-level overviews of the detailed content presented in Modules 3–5. It includes:

2.1 CTD Table of Contents
2.2 Introduction
2.3 Quality Overall Summary (QOS)
2.4 Nonclinical Overview
2.5 Clinical Overview
2.6 Nonclinical Written and Tabulated Summaries
2.7 Clinical Summary (efficacy and safety)

Medical writers and regulatory affairs specialists typically prepare these summaries to help reviewers understand the full dossier quickly. Consistency between summaries and detailed data is critical.

Module 3: Quality Documentation

Module 3 covers information related to the Chemistry, Manufacturing, and Controls (CMC) of the drug product and drug substance:

Contents of Module 3:

3.2.S Drug Substance:
- General information
- Manufacture and control of the API
- Specifications and stability data
3.2.P Drug Product:
- Composition, manufacturing process
- Specifications, analytical procedures
- Container closure system
- Stability data and shelf-life justification

This section often refers to GMP practices. You may include GMP documentation for batch records and manufacturing protocols. Stability testing reports are also part of this module.

Module 4: Nonclinical Study Reports

Module 4 contains the full reports of pharmacology, pharmacokinetics (PK), and toxicology studies:

Study reports on:
- Primary and secondary pharmacodynamics
- Pharmacokinetic studies (ADME)
- Single and repeat-dose toxicity
- Genotoxicity and carcinogenicity
- Reproductive and developmental toxicity
Summaries and integrated reports

These reports support the safety profile of the drug prior to clinical trials. The layout must align with ICH M4S guidance. Ensure all nonclinical studies are conducted per GLP standards.

Module 5: Clinical Study Reports

Module 5 holds the clinical trial data and outcomes that demonstrate the drug’s safety and efficacy in humans. It includes:

Study protocols and statistical plans
Full ICH-compliant study reports (Phase I–III)
Bioavailability and bioequivalence reports
Integrated summaries of safety and efficacy
Post-marketing data (if available)

This is the most voluminous module. Medical writers work closely with biostatisticians and clinical operations teams to compile accurate, well-interpreted reports. Tools like pharmaceutical validation records and audit trail logs also support the data’s integrity.

eCTD Format: A Digital Submission Standard

Most regulatory agencies now require or prefer submissions in eCTD format, which organizes modules into a digitally navigable structure. Benefits include:

Hyperlinked TOCs and bookmarks
Modular submissions and lifecycle management
Faster review processes

Publishing tools like Lorenz DocuBridge or Extedo are commonly used. Ensure the eCTD follows proper XML backbone and regional technical specifications.

CTD Best Practices for Authors:

✅ Keep document numbering and file names consistent across modules
✅ Cross-reference correctly (e.g., refer Module 3 data in Module 2)
✅ Maintain traceability with document metadata
✅ Follow ICH M4, M2, and regional guidance strictly
✅ Conduct internal and external QC reviews before submission

Quality documentation, such as Pharma SOPs, can be referenced within Modules 1 and 3 to demonstrate standard procedures and controls.

Conclusion:

The CTD format has streamlined the global regulatory submission process, improving transparency and harmonization. Each module plays a unique role, and successful submission depends on clarity, accuracy, and completeness across all sections.

As a pharmaceutical documentation professional, understanding and correctly implementing the CTD structure is essential for global market access. Keep your submissions compliant, well-organized, and regulator-friendly.